Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Main finding · Nonadherence (PDC <0.8)Result — go to the resultOdds ratio 1.25 95% CI 1.19–1.31Authors' conclusion
Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.
Study context
- Population
- Nonpregnant adults aged 18–64 years with T2D initiating GLP-1 RA, continuously enrolled in same private insurance plan 6 months before and 1 year after prescription; MarketScan Commercial data (2016–2021)
- Participants
- 61,907 adults
- Exposure
- Highest vs lowest quartile of first 30-day out-of-pocket costs for GLP-1 RA
- Outcome
- Annual proportion of days covered (PDC) for GLP-1 RA and nonadherence (PDC <0.8)
- Follow-up
- 1 year
Main finding
Nonadherence (PDC <0.8)
Odds ratio
1.25
95% CI 1.19–1.31
Q4vs Q1
OR 1.25 (95% CI 1.19–1.31)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Outcomes associated with nonadherence (nonadherent vs adherent) · 1 year after GLP-1 RA initiation
- Diabetes-related hospitalizations or emergency department (ED) visits, IRR
- 1.86 (1.43-2.42) (95% CI)
- Cumulative length of hospitalization, IRR
- 1.56 (1.41-1.72) (95% CI)
- All-cause ED visits, IRR
- 1.38 (1.32-1.45) (95% CI)
- Increased ED-related costs (95% CI)
- $69.81 ($53.54-$86.08)
Original publication
Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. Diabetes Care. Published 9 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →